Efficacy of chemoradiotherapy versus radiation alone in patients with inoperable locally advanced non–small-cell lung cancer

Hung, Ming‐Szu; Wu, Yi-Ming; Chen, Yi-Chuan

doi:10.1097/md.0000000000016167

Cited by 20 publications

(13 citation statements)

References 42 publications

(50 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several metastatic MMs were included in the study of Mohr et al; therefore, they showed lower OS rates. Three reviewed studies reported PFS ranging from 25% to 41%, and CIRT concurrent with chemotherapy exhibited superior PFS compared to CIRT alone, which was also reported elsewhere 28,32 . In addition, T1‐2 tumors were significantly associated with better PFS.…”

Section: Discussionsupporting

confidence: 55%

“…Although including mostly patients at advanced stages, 2‐y OS rate reached 63% in the study of Shirai et al All participants were N0 M0, and 58% used concurrent chemotherapy, which may explain the high survival rates. Koto et al suggested that concurrent chemotherapy was a markedly independent factor for OS, 26 similar to results of concurrent chemo‐RT in patients with inoperable locally advanced nonsmall cell lung cancer 28 . A recent study by Takayasu et al may have included the same patients as Shirai et al, therefore the former publication was not included in this review 29 .…”

Section: Discussionmentioning

confidence: 76%

See 1 more Smart Citation

Efficacy and safety of carbon‐ion radiotherapy for the malignant melanoma: A systematic review

Zhang

et al. 2020

Cancer Medicine

View full text Add to dashboard Cite

Malignant melanomas (MMs) originate from melanocytes in the basal layer of the epidermis, and they are characterized by high malignancy, early metastasis, poor prognosis, and high mortality. Depending on their location, MMs can be classified as cutaneous, uveal or mucosal. Previous studies suggest that average morbidity rates are 16.2 per 100 000 in the United States and 0.383 per 100 000 in Japan. 1 However, MMs incidence increased continuously worldwide. 2,3 MMs were the fifth most common cancer in men and the sixth most common cancer in women in 2018. According to the American Association of Cancer (AJCC) TNM staging system, the 5-year overall survival (5-y OS) rates are approximately 98.2% in patients at stages I/II, 61.7% at stage III, and 15.2% at stage IV. 4 Although stage I MMs are typically associated with good prognoses after surgical treatment only, achieving negative margins in all patients was difficult. Currently available treatment options for patients with MM include radiotherapy (RT), chemotherapy, targeted therapy, and immunotherapy. Adjuvant therapies were

show abstract

Section: Discussionsupporting

confidence: 55%

Section: Discussionmentioning

confidence: 76%

Efficacy and safety of carbon‐ion radiotherapy for the malignant melanoma: A systematic review

Zhang

et al. 2020

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…A 2019 meta-analysis conducted by Hung, et al demonstrated better efficacy of CRT versus single-modality radiotherapy in patients with unresectable stage III NSCLC. However, the study included a younger patient population (54-77 years) while noting that data describing CRT outcomes in the elderly patient population is sparse and under-represented, and therefore, results of the study may not directly apply to the elderly patient population [29]. This study provides an important piece of real-world evidence to fill this gap in knowledge.…”

Section: Plos Onementioning

confidence: 99%

Predictors of chemoradiotherapy versus single modality therapy and overall survival among patients with unresectable, stage III non-small cell lung cancer

et al. 2020

View full text Add to dashboard Cite

Introduction Concurrent chemoradiotherapy (cCRT) was the standard of care for patients with unresectable stage III non-small cell lung cancer (NSCLC) prior to the PACIFIC trial, however, patients also received single modality therapy. This study identified predictors of therapy and differences in overall survival (OS). Methods This retrospective study included stage III NSCLC patients aged �65 years, with �1 claim for systemic therapy (ST) or radiotherapy (RT) within 90 days of diagnosis, identified in SEER-Medicare data (2009-2014). Patients who had overlapping claims for chemotherapy and RT �90 days from start of therapy were classified as having received cCRT. Patients who received sequential CRT or surgical resection of tumor were excluded. Predictors of cCRT were analyzed using logistic regression. OS was compared between therapies using adjusted Cox proportional hazards models. Results Of 3,799 patients identified, 21.7% received ST; 26.3% received RT; and 52.0% received cCRT. cCRT patients tended to be younger (p <0.001), White (p = 0.002), and have a good predicted performance status (p<0.001). Patients who saw all three specialist types (medical oncologist, radiation oncologist, and surgeon) had increased odds of receiving cCRT (p<0.001). ST and RT patients had higher mortality risk versus cCRT patients (hazard ratio

show abstract

“…Globally, bronchogenic carcinoma is the leading cause of cancer-related mortality worldwide [1]. Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancers [2]. Malignant endobronchial obstruction (MEBO) refers to any malignant, mechanical, obstructive process that impedes the airflow within the central airways (trachea, main-stem bronchi, and right bronchus intermedius), and it complicates one third of these cases.…”

Section: Introductionmentioning

confidence: 99%

The value of endobronchial cryotherapy in the management of malignant endobronchial obstruction in patients with inoperable NSCLC: a prospective analysis of clinical and survival outcomes

Rashad

Badawy²,

Ali

et al. 2021

Egypt J Bronchol

View full text Add to dashboard Cite

Background Malignant endobronchial obstruction (MEBO) is the most debilitating complication in non-small cell lung cancer (NSCLC). The therapeutic role of cryotherapy and its impact on survival has not been well addressed. This is to clarify whether the combination of endobronchial cryotherapy (EBCT) and chemoradiotherapy (CRT) improved symptoms, respiratory functions, performance status, and survival outcomes in inoperable NSCLC with symptomatic MEBO compared to that obtained by CRT alone. Results A prospective cohort study included 60 cases presented to Qena University Hospital, Egypt, between December 2016 and May 2019. They were divided into two groups. Group A included 30 patients who were managed with EBCT plus CRT. Group B included 30 patients who were managed with CRT alone. The outcomes assessed were symptoms relief, respiratory function tests (RFT), performance status, and survival outcomes at baseline and 4 weeks of follow-up. Group A patients showed a highly significant improvement in symptoms (cough, dyspnea, and hemoptysis), RFT, 6MWD test, and arterial blood gases, compared to group B. The mean Karnofsky score increased from 57.33±5.67% at baseline to 60.67±6.39% post-EBCT (P=0.036); group A was significantly improved compared to group B (P=0.04). The Kaplan-Meier median survival for all patients was 9.7±0.4 months (95% CI= 8.86–10.54), and group A cases (10.77±0.44 months, 95% CI= 9.9–11.6) was significantly longer than that of group B cases (8.6±0.68 months, 95% CI= 7.3–9.97; T test = 2.631, P=0.011). Conclusion The use of EBCT with CRT for the management of MEBO in symptomatic patients with inoperable NSCLC is an efficient and safe procedure. EBCT improves clinical outcomes, RFT, performance status, and median survival. Trial registration ClinTrial.Gov registration: NCT04710459 on 4/3/2021.

show abstract

Efficacy of chemoradiotherapy versus radiation alone in patients with inoperable locally advanced non–small-cell lung cancer

Abstract: Supplemental Digital Content is available in the text

Cited by 20 publications

References 42 publications

Efficacy and safety of carbon‐ion radiotherapy for the malignant melanoma: A systematic review

Efficacy and safety of carbon‐ion radiotherapy for the malignant melanoma: A systematic review

Predictors of chemoradiotherapy versus single modality therapy and overall survival among patients with unresectable, stage III non-small cell lung cancer

The value of endobronchial cryotherapy in the management of malignant endobronchial obstruction in patients with inoperable NSCLC: a prospective analysis of clinical and survival outcomes

Contact Info

Product

Resources

About